Longeveron ELPIS II Trial Did Not Meet Primary Efficacy Endpoint

Longeveron Inc. reported that its ELPIS II trial did not meet the primary efficacy endpoint, as disclosed in a recent SEC filing. The outcome may impact investor confidence and the company's stock performance, which is currently represented by the ticker LGVN.